Coca-Cola says it is interested in drinks infused with CBD — the non-psychoactive ingredient in marijuana that treats pain but doesn’t get you high. The news pushed cannabis stocks higher Monday.
The world’s largest beverage company may be the next industry giant to jump into the cannabis-drinks business.
Coca-Cola Co. says it’s monitoring the nascent industry and is interested in drinks infused with CBD — the non-psychoactive ingredient in marijuana that treats pain but doesn’t get you high. The Atlanta-based soft-drinks maker is in talks with Canadian marijuana producer Aurora Cannabis to develop the beverages, according to a report from BNN Bloomberg Television.
“We are closely watching the growth of non-psychoactive CBD as an ingredient in functional wellness beverages around the world,” Coca-Cola spokesman Kent Landers said in an emailed statement to Bloomberg News. “The space is evolving quickly. No decisions have been made at this time.” Landers declined to comment on Aurora.
Aurora’s shares surged on the news, jumping 17 percent Monday in Toronto. Other stocks in the cannabis industry got a boost, with British Columbia-based Tilray — a subsidiary of Seattle-based Privateer Holdings — climbing 10.2 percent on the Nasdaq market in response to Coca-Cola’s interest.
Most Read Business Stories
- Is an iPad enough to train Boeing 737 MAX pilots? Famed pilot Sullenberger says he has a better idea
- Airbus racks up more orders over stricken Boeing at Paris Air Show
- Airbus roiled by secret Boeing order for 737 MAX jets that stole the Paris show
- British Airways parent company delivers a massive vote of confidence in the Boeing 737 MAX
- Dish is near a $6 billion deal for T-Mobile, Sprint assets
Coke’s possible foray into the marijuana sector comes as beverage makers are trying to add cannabis as a trendy ingredient while their traditional businesses slow. Last month, Corona beer brewer Constellation Brands announced it will spend $3.8 billion to increase its stake in Canopy Growth, the Canadian marijuana producer with a value that exceeds C$13 billion ($10 billion).
Molson Coors Brewing is starting a joint venture with Quebec’s Hydropothecary to develop cannabis drinks in Canada. Diageo, maker of Guinness beer, is holding discussions with at least three Canadian cannabis producers about a possible deal, BNN Bloomberg reported last month. Heineken’s Lagunitas craft-brewing label has launched a brand specializing in nonalcoholic drinks infused with THC, marijuana’s active ingredient.
Coca-Cola’s statement shows the company has learned from its past missteps picking up on new-drink trends, said Ali Dibadj, a senior analyst at AllianceBernstein with an expertise in U.S. beverage and snack-food companies.
But, he added, “I think you have to be very, very careful with this as a large brand. There are different viewpoints on a product category, and you don’t want to offend too much,” Dibadj said. “You don’t want to be too far ahead on any curve.”
Coca-Cola already has been diversifying as consumption of soda continues to decline. The company, with its iconic brands ranging from Coke and Sprite to Powerade, announced it will acquire the Costa Coffee chain for $5.1 billion in August and has expanded into other products including juice, tea and mineral water over the past decade.
The discussions with Aurora are focused on CBD-infused drinks to ease inflammation, pain and cramping, according to the BNN Bloomberg report.
CBD, or cannabidiol, is the chemical in the pot plant often used for medicinal purposes and doesn’t produce the high that comes from THC, or tetrahydrocannabinol.
There are no guarantees of any deal between Aurora and Coca-Cola, according to the report.
Heather MacGregor, a spokeswoman for Aurora, said in an emailed statement that the cannabis producer has expressed specific interest in the infused-beverage space, and intends to enter that market, BNN Bloomberg’s David George-Cosh reported.
While marijuana remains illegal at the national level in the United States, there is growing acceptance of the use of CBD derived from marijuana to treat illnesses ranging from chronic pain to anxiety and epilepsy. The first-ever medical treatment derived from a marijuana plant will hit the U.S. market soon, after regulators in June gave an epilepsy treatment by GW Pharmaceuticals the green light.
Aurora is Canada’s third-largest pot company, with a market value of C$8.7 billion. The Edmonton, Alberta-based company has soared along with other pot stocks in Canada as the country gears up to become the first Group of Seven nation to legalize cannabis on Oct. 17. The BI Canada Cannabis Competitive Peers Index has more than doubled in the past 12 months, though it has dropped 24 percent in 2018 on concern that the stocks are overvalued.